Thomas Kirk Purchases 72,000 Shares of Myomo (NYSEAMERICAN:MYO) Stock

Myomo, Inc. (NYSEAMERICAN:MYO) Director Thomas Kirk acquired 72,000 shares of Myomo stock in a transaction that occurred on Friday, March 13th. The shares were bought at an average price of $0.71 per share, for a total transaction of $51,120.00. Following the transaction, the director owned 553,857 shares of the company’s stock, valued at $393,238.47. This represents a 14.94% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Myomo Stock Performance

NYSEAMERICAN MYO opened at $0.72 on Wednesday. The company has a debt-to-equity ratio of 0.98, a quick ratio of 2.93 and a current ratio of 3.30. The stock’s fifty day moving average is $0.83 and its two-hundred day moving average is $0.91. The firm has a market capitalization of $27.77 million, a P/E ratio of -1.95 and a beta of 1.17. Myomo, Inc. has a fifty-two week low of $0.63 and a fifty-two week high of $5.62.

Hedge Funds Weigh In On Myomo

Several large investors have recently modified their holdings of MYO. XTX Topco Ltd purchased a new position in shares of Myomo during the 4th quarter worth $148,000. AQR Capital Management LLC lifted its position in Myomo by 47.8% in the fourth quarter. AQR Capital Management LLC now owns 434,376 shares of the company’s stock valued at $395,000 after buying an additional 140,427 shares during the last quarter. State Street Corp boosted its stake in Myomo by 5.1% during the fourth quarter. State Street Corp now owns 399,853 shares of the company’s stock worth $364,000 after buying an additional 19,563 shares during the period. Wells Fargo & Company MN boosted its stake in Myomo by 103.1% during the fourth quarter. Wells Fargo & Company MN now owns 38,707 shares of the company’s stock worth $35,000 after buying an additional 19,646 shares during the period. Finally, Jane Street Group LLC acquired a new stake in shares of Myomo during the fourth quarter valued at about $64,000. Institutional investors and hedge funds own 44.99% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on MYO. Ascendiant Capital Markets cut their price objective on shares of Myomo from $10.50 to $10.00 and set a “buy” rating for the company in a research report on Friday, November 21st. Craig Hallum reiterated a “buy” rating on shares of Myomo in a report on Tuesday, March 10th. Four analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $7.67.

About Myomo

Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.

Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.